1287 related articles for article (PubMed ID: 30327274)
1. Systemic Treatment of Metastatic Clear Cell Renal Cell Carcinoma in 2018: Current Paradigms, Use of Immunotherapy, and Future Directions.
Lalani AA; McGregor BA; Albiges L; Choueiri TK; Motzer R; Powles T; Wood C; Bex A
Eur Urol; 2019 Jan; 75(1):100-110. PubMed ID: 30327274
[TBL] [Abstract][Full Text] [Related]
2. Overview of Current and Future First-Line Systemic Therapy for Metastatic Clear Cell Renal Cell Carcinoma.
Gill DM; Hahn AW; Hale P; Maughan BL
Curr Treat Options Oncol; 2018 Jan; 19(1):6. PubMed ID: 29368125
[TBL] [Abstract][Full Text] [Related]
3. Sequencing and Combination of Systemic Therapy in Metastatic Renal Cell Carcinoma.
de Velasco G; Bex A; Albiges L; Powles T; Rini BI; Motzer RJ; Heng DYC; Escudier B
Eur Urol Oncol; 2019 Sep; 2(5):505-514. PubMed ID: 31377308
[TBL] [Abstract][Full Text] [Related]
4. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors.
Shah AY; Kotecha RR; Lemke EA; Chandramohan A; Chaim JL; Msaouel P; Xiao L; Gao J; Campbell MT; Zurita AJ; Wang J; Corn PG; Jonasch E; Motzer RJ; Sharma P; Voss MH; Tannir NM
Eur J Cancer; 2019 Jun; 114():67-75. PubMed ID: 31075726
[TBL] [Abstract][Full Text] [Related]
5. Current and emerging first-line systemic therapies in metastatic clear-cell renal cell carcinoma.
Tegos T; Tegos K; Dimitriadou A; Dimitriadis G
J BUON; 2019; 24(4):1340-1353. PubMed ID: 31646776
[TBL] [Abstract][Full Text] [Related]
6. [Immunotherapy for renal cell carcinoma - current status].
Grimm MO; Foller S
Aktuelle Urol; 2018 Apr; 49(2):187-191. PubMed ID: 29587324
[TBL] [Abstract][Full Text] [Related]
7. Advances in the Treatment of Metastatic Renal Cell Carcinoma.
Bergerot P; Burns K; Prajapati D; Fox R; Salgia M; Pal SK
Cancer Treat Res; 2018; 175():127-137. PubMed ID: 30168120
[TBL] [Abstract][Full Text] [Related]
8. Overview of current and future systemic therapy for metastatic renal cell carcinoma.
Osawa T; Takeuchi A; Kojima T; Shinohara N; Eto M; Nishiyama H
Jpn J Clin Oncol; 2019 May; 49(5):395-403. PubMed ID: 30722031
[TBL] [Abstract][Full Text] [Related]
9. The Association Between PD-L1 Expression and the Clinical Outcomes to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma.
Shin SJ; Jeon YK; Cho YM; Lee JL; Chung DH; Park JY; Go H
Oncologist; 2015 Nov; 20(11):1253-60. PubMed ID: 26424759
[TBL] [Abstract][Full Text] [Related]
10. Impact of Clinicopathological Features on Survival in Patients Treated with First-line Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: A Meta-analysis of Randomized Clinical Trials.
Rizzo A; Mollica V; Santoni M; Ricci AD; Rosellini M; Marchetti A; Montironi R; Ardizzoni A; Massari F
Eur Urol Focus; 2022 Mar; 8(2):514-521. PubMed ID: 33714725
[TBL] [Abstract][Full Text] [Related]
11. The Changing Landscape of Management of Metastatic Renal Cell Carcinoma: Current Treatment Options and Future Directions.
Salgia NJ; Dara Y; Bergerot P; Salgia M; Pal SK
Curr Treat Options Oncol; 2019 Apr; 20(5):41. PubMed ID: 30937639
[TBL] [Abstract][Full Text] [Related]
12. Role of immunotherapy in kidney cancer.
Nazzani S; Bazinet A; Karakiewicz PI
Curr Opin Support Palliat Care; 2018 Sep; 12(3):325-333. PubMed ID: 30048250
[TBL] [Abstract][Full Text] [Related]
13. Vascular endothelial growth factor-targeted therapy in patients with renal cell carcinoma pretreated with immune checkpoint inhibitors: A systematic literature review.
Albiges L; McGregor BA; Heng DYC; Procopio G; de Velasco G; Taguieva-Pioger N; Martín-Couce L; Tannir NM; Powles T
Cancer Treat Rev; 2024 Jan; 122():102652. PubMed ID: 37980876
[TBL] [Abstract][Full Text] [Related]
14. The Current and Evolving Landscape of First-Line Treatments for Advanced Renal Cell Carcinoma.
Calvo E; Porta C; Grünwald V; Escudier B
Oncologist; 2019 Mar; 24(3):338-348. PubMed ID: 30158285
[TBL] [Abstract][Full Text] [Related]
15. Game of thrones: immunotherapy versus molecular targeted therapy in renal cell cancer scenarios.
Cetin B; Kosar A
Int Urol Nephrol; 2019 Dec; 51(12):2107-2117. PubMed ID: 31468288
[TBL] [Abstract][Full Text] [Related]
16. Immune checkpoint inhibitors combined with tyrosine kinase inhibitors or immunotherapy for treatment-naïve metastatic clear-cell renal cell carcinoma-A network meta-analysis. Focus on cabozantinib combined with nivolumab.
Niewada M; Macioch T; Konarska M; Mela A; Goszczyński A; Przekopińska B; Rajkiewicz K; Wysocki P; Krzakowski M
Front Pharmacol; 2022; 13():1063178. PubMed ID: 36937206
[No Abstract] [Full Text] [Related]
17. Combining Immune Checkpoint and VEGFR Inhibition in Favorable Risk and Elderly Patients With Metastatic Renal Cell Carcinoma.
Varkaris A; Xu W; Davis RB; Healy B; McDermott DF
Clin Genitourin Cancer; 2020 Jun; 18(3):179-184.e3. PubMed ID: 32144046
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant Therapy for High Risk Localized Kidney Cancer: Emerging Evidence and Future Clinical Trials.
Lenis AT; Donin NM; Johnson DC; Faiena I; Salmasi A; Drakaki A; Belldegrun A; Pantuck A; Chamie K
J Urol; 2018 Jan; 199(1):43-52. PubMed ID: 28479237
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy Is Changing First-Line Treatment of Metastatic Renal-Cell Carcinoma.
Labriola MK; Batich KA; Zhu J; McNamara MA; Harrison MR; Armstrong AJ; George DJ; Zhang T
Clin Genitourin Cancer; 2019 Jun; 17(3):e513-e521. PubMed ID: 30858035
[TBL] [Abstract][Full Text] [Related]
20. Immune Checkpoint Inhibitors: Toward New Paradigms in Renal Cell Carcinoma.
Flippot R; Escudier B; Albiges L
Drugs; 2018 Sep; 78(14):1443-1457. PubMed ID: 30187355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
